This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
2023 Biopharma Pharma 
Fierce Pharma
DECEMBER 20, 2022
2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products. Tue, 12/20/2022 - 13:39.
254 254 
Fierce Pharma
MAY 16, 2024
The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year.
288 This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MAY 24, 2023
Biopharma staffers exhausted and susceptible to burnout, report says kdunleavy Wed, 05/24/2023 - 16:52
306 306 
Fierce Pharma
MAY 18, 2023
The Top Line': 2023's biopharma layoffs, plus this week's headlines tcarey Thu, 05/18/2023 - 16:13
144 144 
Fierce Pharma
APRIL 18, 2023
Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48
245 
Fierce Pharma
SEPTEMBER 7, 2023
Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios.
327 
Fierce Pharma
JANUARY 23, 2023
Call for nominations: The most influential people in biopharma in 2023 esagonowsky Mon, 01/23/2023 - 14:32
130 130 
Fierce Pharma
APRIL 12, 2024
Merck CEO Robert Davis has cracked the $20-million mark in annual pay for the first time, putting him in an exclusive club of biopharma heavy hitters. Merck CEO Robert Davis has cracked the $20-million mark in annual pay for the first time, putting him in an exclusive club of biopharma heavy hitters.
227 227 
Fierce Pharma
MAY 16, 2023
FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report aliu Tue, 05/16/2023 - 09:41
293 293 
Fierce Pharma
MAY 22, 2023
Pfizer, Moderna among many biopharma giants to post Q1 sales declines, as Novo Nordisk led growth charge kdunleavy Mon, 05/22/2023 - 13:04
274 
Fierce Pharma
MARCH 21, 2023
Biopharma industry lobbies for tax breaks related to US-based manufacturing kdunleavy Tue, 03/21/2023 - 11:14
252 
Fierce Pharma
JANUARY 16, 2024
2023 was riddled with labor strikes across industries as workers lobbied for higher pay amid economic headwinds that shook up the global economy. | A USA Today review of millions of Glassdoor ratings found that employees in the biopharma industry are the most satisfied with their pay compared with other fields.
218 218 
Fierce Pharma
JANUARY 8, 2024
Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. Morgan Healthcare Conference. |
243 
Fierce Pharma
NOVEMBER 22, 2022
2023 preview: Despite Biden's drug pricing win, the biopharma industry is not 'anywhere near done with this conversation'. esagonowsky. Tue, 11/22/2022 - 14:22.
130 130 
European Pharmaceutical Review
SEPTEMBER 15, 2023
For its 20 th anniversary, more than 180 entries across 12 categories have been narrowed down to determine the finalists the upcoming CPHI Pharma Awards. Award winners will be revealed at a networking reception on the first day of CPHI Barcelona 2023, which is running from 24-26 October. Are you coming to the CPHI Barcelona 2023?
119 
Fierce Pharma
MAY 9, 2023
Let's make a deal: Conditions are right for biopharma M&A to break out, analysts say kdunleavy Tue, 05/09/2023 - 10:18
224 224 
Fierce Pharma
MAY 25, 2023
The Top Line': The 20 most influential people in biopharma, plus this week's headlines tcarey Thu, 05/25/2023 - 14:21
193 193 
Fierce Pharma
APRIL 19, 2023
Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats up aliu Wed, 04/19/2023 - 14:39
200 200 
Fierce Pharma
DECEMBER 22, 2023
Even with the Federal Trade Commission keeping a watchful eye on the biopharma industry and the economic landscape giving some players pause, mergers and acquisitions are back on the rise.
343 343 
Fierce Pharma
MAY 9, 2023
We want your stories: Biopharma's collective memory of COVID—in photographs aliu Tue, 05/09/2023 - 14:56
157 157 
Pharma Pathway
FEBRUARY 28, 2023
Hetero Biopharma-Walk-In Interview for M.Sc/ B.Sc/ Diploma in Production On 4th Mar’ 2023 Job Description Greetings from Hetero Biopharma !!! Walk-In Interview for M.Sc/ B.Sc/ Diploma in Production @ Hetero Biopharma Department: Production Designation: Executive to Sr. 7-2-A2, Sanath Nagar, Opp.
81 
Pharma Pathway
FEBRUARY 23, 2023
Position: 26 Date: 26th Feb’ 2023 Time: 10:00 AM to 03:00 PM Venue: Celebrity Biopharma Limited, Vill -Panga Hilltop, Estate Via Jharmajri Distt. Celebrity Biopharma Limited (Aishwarya Group)-Walk-In Interviews for QA/ QC/ Production On 26th Feb’ 2023
80 
Fierce Pharma
FEBRUARY 21, 2024
In a year that started with more than two-thirds of biopharma companies posting | While Novo Nordisk and Eli Lilly continued to be the biopharma industry growth leaders in the fourth quarter of 2023, many other drugmakers also delivered big gains, including Daiichi Sankyo, Amgen, Teva, GSK and Novartis.
275 
Fierce Pharma
JANUARY 3, 2024
Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming the market wi | Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk (..)
284 
Pharma Pathway
FEBRUARY 14, 2023
Manvi Biopharma Pvt. Ltd- Walk-In Interviews for Production/ Quality Control On 15th Feb’ 2023 Job Description Walk-In Interviews for Production/ Quality Control On 15th Feb’ 2023 @ Manvi Biopharma Pvt. Manvi Biopharma Pvt. Ltd Department: Production/ Quality Control Posts: Chemist/ Sr.
52 
European Pharmaceutical Review
FEBRUARY 21, 2023
Included in this issue of European Pharmaceutical Review : FOREWORD Accelerating drug development David Elder, David P Elder Consultancy RAMAN SPECTROSCOPY Shining a light on Raman for microbiological analysis Tim Sandle, Bio Products Laboratory LIMS Overcoming barriers to capturing data in a laboratory Samantha Kanza, University of Southampton ENVIRONMENTAL (..)
111 
Pharma Pathway
FEBRUARY 3, 2023
Hetero Biopharma-Walk-In Interview for M.Sc/ B.Tech Biochemistry/ Biotechnology in Production On 4th Feb’ 2023 Job Description Greetings from Hetero Biopharma !!! Walk-In Interview for M.Sc/ B.Tech Biochemistry/ Biotechnology in Production @ Hetero Biopharma Department: Production Designation: Executive to Sr.
52 
PharmExec
OCTOBER 13, 2023
Exploring the pharma and biotech financing, M&A, and stock market pictures through the first half of 2023—and implications for the future, as market challenges continue to weigh heavily in senior management decision-making.
104 
European Pharmaceutical Review
DECEMBER 20, 2023
In Q1 2023, the European Commission (EC) announced proposed changes to EU pharmaceutical legislation. 1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. analysis (Source: L.E.K) What are the latest amendments?
98 
Zymewire
JANUARY 24, 2024
Unlocking the financial pulse of the biotech and pharma industry. A must-read for sales professionals navigating the terrain of biotech and pharma funding
52 
European Pharmaceutical Review
OCTOBER 2, 2023
CPHI Barcelona, the renowned global pharma event, is set to take centre stage from 24 to 26 October 2023 at Fira Barcelona Gran Via, Spain. CPHI creates connections and inspires partnerships across the global pharma community. CPHI creates connections and inspires partnerships across the global pharma community.
105 
European Pharmaceutical Review
AUGUST 24, 2023
This strategy shift did not occur overnight, but evolved in response to the changing biopharma landscape. Even among the leaders of the biopharma sector, few companies have a significant presence across these platforms, Baral highlighted. Venture funding in 2022 came in at about $13.7 billion, down from the high of 2021.
98 
pharmaphorum
DECEMBER 15, 2022
The month of November saw a number of notable hires and personnel moves in biotech and pharma. New CEO in at Angelini Pharma. Jacopo Andreose will take over as CEO of Angelini Pharma, a subsidiary of Angelini Industries, in February 2023, the Italian company announced last month. Other biopharma hires.
52 
Clarivate
JULY 24, 2023
Biopharma and medtech brands made up a dozen of the Clarivate Top 100 New Brands for 2023, as the life science industries continued to show a muscular approach to protecting their intellectual property. The post Pharmas and medtechs flex brand protection among Top 100 New Brands for 2023 appeared first on Clarivate.
52 
Clarivate
MAY 8, 2024
A glance at the 2023 and early 2024 life science dealmaking environment shows fewer, but higher-value, transactions. As a result, 2023 saw an upsurge in merger and acquisition (M&A) and deal activity. According to BioWorld, M&A values in 2023 jumped 80% over 2022, and deal values reached BioWorld’s highest level ever recorded.
59 
European Pharmaceutical Review
OCTOBER 27, 2022
Ahead of the world’s largest pharma event, CPHI Frankfurt – hosted at the Frankfurt Messe (1-3 November, 2022) – part i of the CPHI Annual Report looks ahead at the opportunities for biologics outsourcing and contract manufacturing organisastions (CMOs) in 2023. percent in 2022.
98 
MedCity News
MARCH 24, 2024
based pharma companies. The survey was conducted in late 2023 and results were reported this month. Lack of automation is the top challenge facing commercialization teams, according to a survey of executives at U.S.-based
91 
MedCity News
DECEMBER 15, 2022
2023 is shaping up to be a crucial year for everyone involved – and affected – by the pharmaceutical industry. It’s likely to be a year of experimentation for payers – and defensiveness for drug makers.
104 
Clarivate
JANUARY 10, 2023
However, because they are highly targeted, they address smaller potential patient cohorts than the mass-market treatments of yore, forcing pharmas to thread the needle on pricing in order to recoup the costs of development and fund the next cycle of innovation. The post The Drugs to Watch in 2023 appeared first on Clarivate.
59 
pharmaphorum
DECEMBER 23, 2022
And in 2023, these investments will hopefully pay off. With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance. Marketing data will surpass health data as a leading signal for pharma advertisers.
94 
PharmaTech
JULY 17, 2023
Unlock the full potential of your pharma/biopharma laboratory with our comprehensive guide on mastering liquid handling techniques for any liquid type.
52 
Clarivate
OCTOBER 31, 2023
These years witnessed significant troughs in pharma financing, a drop in the capital markets, and an IPO window that remained firmly shut. Big pharma is still keen to access good technology, science, and assets, in many cases to plug a patent-expiry-shaped hole in their coffers. In short, the biotech bubble had burst. Pfizer’s $11.6
52 
European Pharmaceutical Review
JANUARY 12, 2023
Out of 19 companies honoured with the 2022 Terra Carta Seal, the three pharma companies awarded were: GlaxoSmithKline PLC. Being awarded the 2022 Terra Carta Seal is confirmation of GSK demonstrating its commitment to climate responsibility for its supply chain in force from 2023. Samsung Biologics.
105 
PharmaTech
JANUARY 9, 2024
Bradley Grobler, Vice President of Sales, Pharma & Biopharma Europe, describes how Actylis meets global demands for (bio)pharmaceutical development and manufacturing programs during CPhI 2023.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content